Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28984317 | 0.80 | KDM4E (0.60) | CYP1A2ALDH1A1KDM4EADORA3ADORA1 | |
| SCHEMBL3400524 | 0.79 | ALDH1A1 (0.51) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL10181023 | 0.79 | CYP1A2 (0.53) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL27884234 | 0.78 | MTNR1A (0.43) | SMN1; SMN2HMGCRTDP1POLBMAPT | |
| SCHEMBL577793 | 0.77 | ALDH1A1 (0.52) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL5092353 | 0.77 | CYP1A2 (0.57) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL3405403 | 0.77 | KDM4E (0.55) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL12883030 | 0.75 | MAPT (0.50) | CYP1A2ALDH1A1KDM4EADORA3ADORA1 | |
| SCHEMBL577637 | 0.75 | POLB (0.53) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL984078 | 0.75 | CYP1A2 (0.50) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | CYP1A2 2666/4885ALDH1A1 1220/4885KDM4E 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.